Gossamer Bio Inc. [GOSS] Chief Scientific Officer makes an insider acquire of 6,934 shares worth 49,994.

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Gossamer Bio Inc. shares valued at $49,994 were purchased by Carter Laura on Jul 15. At $7.21 per share, Carter Laura acquired 6,934 shares. The insider’s holdings grew to 87,168 shares worth approximately $1.07 million following the completion of this transaction.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.

Sponsored


Also, Christian Waage purchased 6,934 shares, netting a total of over 49,994 in proceeds. Following the buying of shares at $7.21 each, the insider now holds 13,888 shares.

Before that, Giraudo Bryan had added 13,869 shares to its account. In a trade valued at $99,995, the COO/CFO bought Gossamer Bio Inc. shares for $7.21 each. Upon closing the transaction, the insider’s holdings increased to 13,869 shares, worth approximately $0.26 million.

As published in their initiating research note from JP Morgan on September 21, 2022, Gossamer Bio Inc. [GOSS] has been a Neutral and the price target has been revised to $17. This represents a 27.76% premium over Thursday’s closing price. Analysts at Wedbush started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid September. As of April 18, 2022, Raymond James has initiated its “an Outperform” rating for GOSS. Earlier on April 06, 2022, UBS initiated its rating. Their recommendation was “a Buy” for GOSS stock.

Analyzing GOSS’s Price Performance

On Thursday, Gossamer Bio Inc. [NASDAQ: GOSS] plunged -2.23% to $12.28. The stock’s lowest price that day was $11.97, but it reached a high of $12.58 in the same session. During the last five days, there has been a drop of approximately -11.14%. Over the course of the year, Gossamer Bio Inc. shares have jumped approximately 8.58%. Shares of the company reached a 52-week high of $15.19 on 08/25/22 and a 52-week low of $5.64 on 06/16/22. A 50-day SMA is recorded $13.14, while a 200-day SMA reached $9.97. Nevertheless, trading volume fell to 1.01 million shares from 2.36 million shares the previous day.

Support And Resistance Levels for Gossamer Bio Inc. (GOSS)

According to the 24-hour chart, there is a support level at 11.97, which, if violated, would cause prices to drop to 11.67. In the upper region, resistance lies at 12.58. The next price resistance is at 12.89. RSI (Relative Strength Index) is 39.15 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.97, which suggests the price will decrease in the coming days. Percent R is at 89.74%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Is Gossamer Bio Inc. subject to short interest?

Stocks of Gossamer Bio Inc. saw a sharp rise in short interest on Jul 14, 2022 jumping by 1.42 million shares to 13.51 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 12.09 million shares. A jump of 10.51% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.94 of the overall float, the days-to-cover ratio (short ratio) jumped to 6.94.

Which companies own the most shares of Gossamer Bio Inc. (GOSS)?

According to HHLR Advisors Ltd. filings, the company currently owns 7,420,974 shares, which is about 7.90% of the total GOSS shares outstanding. With the completion of the buy transaction, The Vanguard Group, Inc.’s stake is now worth $79,676,555. BlackRock Fund Advisors reduced a -2.81% interest valued at $62.29 million while SSgA Funds Management, Inc. purchased a 567,264 stake. A total of 0 shares of Gossamer Bio Inc. were bought by Federated Global Investment Manag during the quarter, and 194,931 were bought by Octagon Capital Advisors LP. In its current portfolio, Invus Public Equities Advisors LL holds 2,358,968 shares valued at $32.91 million.

In terms of Gossamer Bio Inc. share price expectations, FactSet research, analysts set an average price target of $18.50 in the next 12 months, up nearly 43.31% from the previous closing price of $12.56. Analysts anticipate Gossamer Bio Inc. stock to reach $24.00 by 2022, with the lowest price target being $15.00. In spite of this, 12 analysts ranked Gossamer Bio Inc. stock as a Buy at the end of 2022. On January 10, 2022, SMBC Nikko assigned a price target of “an Outperform” to the stock and upgraded coverage with a $24.

LEAVE A REPLY

Please enter your comment!
Please enter your name here